Defence

Shell Asset Management Co. reduces stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)


Shell Asset Management Co. reduced its position in Halozyme Therapeutics, Inc. (NASDAQ: HALOGet a rating) by 12.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,038 shares of the biopharmaceutical company’s stock after selling 1,188 shares during the period. Shell Asset Management Co.’s holdings. holdings in Halozyme Therapeutics were worth $321,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Verdence Capital Advisors LLC boosted its position in shares of Halozyme Therapeutics by 1.8% in the first quarter. Verdence Capital Advisors LLC now owns 14,021 shares of the biopharmaceutical company’s stock valued at $559,000 after buying an additional 251 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Halozyme Therapeutics by 0.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 48,612 shares of the biopharmaceutical company’s stock worth $1,955,000 after buying an additional 337 shares in the last quarter. Fifth Third Bancorp boosted its position in Halozyme Therapeutics by 4.7% during the fourth quarter. Fifth Third Bancorp now owns 11,793 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 534 shares during the period. Mutual of America Capital Management LLC boosted its position in Halozyme Therapeutics by 0.5% during the fourth quarter. Mutual of America Capital Management LLC now owns 125,933 shares of the biopharmaceutical company’s stock valued at $5,064,000 after buying an additional 633 shares during the period. Finally, Lazard Asset Management LLC boosted its position in Halozyme Therapeutics by 25.2% during the fourth quarter. Lazard Asset Management LLC now owns 3,177 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 639 shares during the period. Currently, 92.53% of the shares are owned by hedge funds and other institutional investors.

Analysts set new price targets

A number of equities research analysts have issued reports on HALO shares. Goldman Sachs Group boosted their price target on Halozyme Therapeutics from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, May 26th. SVB Leerink started coverage on Halozyme Therapeutics in a research report on Monday, May 23rd. They set an “outperform” rating and a $52.00 target price on the stock. finally StockNews.com downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $52.33, according to MarketBeat.com.

Halozyme Therapeutics trades down 0.6%

HALO opened at $45.13 on Friday. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 15.09, a P/E/G ratio of 0.74 and a beta of 1.20. The stock has a 50-day moving average of $47.00 and a 200-day moving average of $41.32. Halozyme Therapeutics, Inc. has a 1-year low of $31.36 and a 1-year high of $52.98. The company has a debt-to-equity ratio of 3.03, a gearing ratio of 8.42, and a current ratio of 8.85.

Halozyme Therapeutics (NASDAQ: HALOGet a rating) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.02). Halozyme Therapeutics had a return on equity of 132.71% and a net margin of 92.23%. The firm had revenue of $117.30 million for the quarter, compared to the consensus estimate of $128.25 million. During the same period last year, the company earned $0.34 per share. The company’s revenue for the quarter grew by 31.8% compared to the same quarter last year. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 2.06 earnings per share for the current year.

Halozyme Therapeutics Company Profile

(Get a rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform in the US, Switzerland, Ireland, Belgium, Japan and internationally. The company’s products are based on ENHANZE drug delivery technology, a patented recombinant human hyaluranidase enzyme (rHuPH20), which enables the subcutaneous administration of injectable biologics such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and liquids.

Read more

Want to see what other hedge funds hold HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ: HALOGet a rating).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)



Get Halozyme Therapeutics News and Ratings Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halozyme Therapeutics and related companies. MarketBeat.com’s FREE Daily E-Newsletter.

https://www.defenseworld.net/2022/08/06/shell-asset-management-co-decreases-stake-in-halozyme-therapeutics-inc-nasdaqhalo.html Shell Asset Management Co. reduces stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Back to top button